Compare MGM Resorts International (MGM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Twist Bioscience Corp — how do they compare? MGM Resorts International trades at $30.3 (market cap $7.55B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Twist Bioscience Corp for 27 Days on average.
| MGM | TWST | |
|---|---|---|
Market Cap | $7.55B | $10.08B |
Volume | 5,342,346 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $205.00 |
52-Week Low | $30.00 | $25.45 |
Typical Hold Time | 91 Days | 27 Days |
Enterprise Value | $34.85B | $10.01B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day, reflecting recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock is technically bearish with key support at $29, while fundamentals show mixed signals: revenue growth is steady but net income margin has compressed to 2.4% in 2025. Analyst consensus remains bullish with a $48.75 price target, though near-term sentiment is pressured by deal uncertainty.
The outlook hinges on MGM's ability to stabilize earnings and potentially pursue strategic alternatives like a bid for People Inc. Upside exists if management executes on value-unlocking initiatives, but risks include integration challenges, high debt levels, and macroeconomic sensitivity. The current price offers a discount to analyst targets, presenting a contrarian opportunity amid weak sentiment.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
